Avixgen Overview
- Year Founded
-
2000
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
M&A
- (Cancelled)
- Latest Deal Amount
-
$11.6M
- Investors
-
8
Avixgen General Information
Description
Developer of a drug delivery technology designed for virus-caused diseases. The company's research focuses on formulating therapies and medications to be used in the treatment of human immunodeficiency virus infection and acquired immune deficiency syndrome, enabling healthcare providers to implement new forms of therapies for the diseases.
Contact Information
Website
www.avixgen.comCorporate Office
- 254 Beotkkot-ro, Geumcheon-gu
- World Meridien 1, Gasan-dong
- Seoul, 913-914
- South Korea
Corporate Office
- 254 Beotkkot-ro, Geumcheon-gu
- World Meridien 1, Gasan-dong
- Seoul, 913-914
- South Korea
Avixgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | $11.6M | Cancelled | Clinical Trials - Phase 2 | |||
| 3. Later Stage VC (Series C) | 29-Sep-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Later Stage VC (Series B) | 28-Jun-2018 | $9.1M | $14.6M | Completed | Clinical Trials - Phase 2 | |
| 1. Later Stage VC (Series A) | 01-Mar-2015 | $5.44M | $5.44M | Completed | Pre-Clinical Trials |
Avixgen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Avixgen Patents
Avixgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026014691-A1 | Eye drop composition comprising imatinib | Pending | 08-Jul-2024 | ||
| EP-4656652-A1 | Novel brain disease therapeutic and use thereof | Pending | 26-Jan-2023 | ||
| US-20260226107-A1 | Novel brain disease therapeutic and use thereof | Pending | 26-Jan-2023 | ||
| WO-2024158194-A1 | Novel brain disease therapeutic and use thereof | Inactive | 26-Jan-2023 | ||
| WO-2024117321-A1 | Cell membrane penetrating peptide, and intracellular carrier including same | Inactive | 01-Dec-2022 |
Avixgen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avixgen Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hyundai Venture Investment Corporation | Venture Capital | Minority | ||
| Renaissance Asset Management (Korea) | Asset Manager | Minority | ||
| Korea Investment Trust Management | Asset Manager | Minority | ||
| Wonik Investment Partners | PE/Buyout | Minority | ||
| HB Investment | Venture Capital | Minority |
Avixgen FAQs
-
When was Avixgen founded?
Avixgen was founded in 2000.
-
Where is Avixgen headquartered?
Avixgen is headquartered in Seoul, South Korea.
-
What is the size of Avixgen?
Avixgen has 13 total employees.
-
What industry is Avixgen in?
Avixgen’s primary industry is Drug Discovery.
-
Is Avixgen a private or public company?
Avixgen is a Private company.
-
What is the current valuation of Avixgen?
The current valuation of Avixgen is .
-
What is Avixgen’s current revenue?
The current revenue for Avixgen is .
-
How much funding has Avixgen raised over time?
Avixgen has raised $23.4M.
-
Who are Avixgen’s investors?
Hyundai Venture Investment Corporation, Renaissance Asset Management (Korea), Korea Investment Trust Management, Wonik Investment Partners, and HB Investment are 5 of 8 investors who have invested in Avixgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
